Mr. Dwyer is a science-based business leader with over 40 years of experience in the biopharmaceutical industry. Mr. Dwyer serves as Chief Business Officer and corporate secretary of Vivani and served as CBO of Nano Precision Medical (NPM) since 2021 until its acquisition by Vivani in September 2022. Prior to this, Mr. Dwyer was consultant to NPM and an observer to NPM's Board of Directors from 2016-2019. From 1995–2019, Mr. Dwyer held leadership positions at AstraZeneca in business development, US commercial brand management, sales, and drug development. Mr. Dwyer co-led the $2.7B acquisition of ZS Pharma and the $1.2B licensing agreement with Targacept. Mr. Dwyer was also US commercial leader for Toprol-XL (hypertension), Onglyza (diabetes), Seroquel (bipolar disorder) and Abraxane (cancer). At Cephalon (now Teva Pharmaceuticals) Mr. Dwyer was the head of regulatory affairs from 1993–1995 and from 1986–1993 he was with Rhone-Poulenc Rorer (now Sanofi-Aventis).

Mr. Dwyer is a graduate of the University of Central Connecticut and Temple University Fox School of Business (MBA).